NCM
APTO

Nantahala Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Nantahala Capital Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,578
Closed -$31.8K – 157
2024
Q3 		$31.8K Hold
2,578
– – ﹤0.01% 134
2024
Q2 		$58.7K Sell
2,578
-373
-13% -$12.7K ﹤0.01% 127
2024
Q1 		$147K Sell
2,951
-1,053
-26% -$60.2K 0.01% 113
2023
Q4 		$305K Sell
4,004
-545
-12% -$42.3K 0.02% 117
2023
Q3 		$382K Sell
4,549
-325
-7% -$38.3K 0.03% 115
2023
Q2 		$679K Sell
4,874
-6,190
-56% -$1.28M 0.07% 100
2023
Q1 		$3.19M Sell
11,064
-2,387
-18% -$693K 0.24% 64
2022
Q4 		$3.51M Sell
13,451
-1,857
-12% -$499K 0.23% 60
2022
Q3 		$4.1M Sell
15,308
-765
-5% -$264K 0.27% 54
2022
Q2 		$5.37M Sell
16,073
-199
-1% -$95.2K 0.27% 61
2022
Q1 		$9.96M Sell
16,272
-627
-4% -$347K 0.44% 42
2021
Q4 		$10.3M Buy
16,899
+553
+3% +$520K 0.36% 54
2021
Q3 		$16M Sell
16,346
-413
-2% -$517K 0.51% 48
2021
Q2 		$25M Sell
16,759
-439
-3% -$956K 0.71% 34
2021
Q1 		$46.2M Buy
17,198
+1,037
+6% +$2.06M 1.35% 18
2020
Q4 		$31.9M Buy
16,161
+852
+6% +$2M 0.99% 25
2020
Q3 		$41.3M Buy
15,309
+2,027
+15% +$5.05M 1.26% 13
2020
Q2 		$37.7M Sell
13,282
-716
-5% -$2.31M 1.14% 22
2020
Q1 		$37.4M Buy
13,998
+545
+4% +$1.63M 1.4% 18
2019
Q4 		$34.3M Buy
13,453
+3,970
+42% +$5.17M 1.06% 27
2019
Q3 		$8.9M Buy
9,483
+1,901
+25% +$2.16M 0.33% 57
2019
Q2 		$8.9M Buy
7,582
+7,444
+5,394% +$6.85M 0.27% 57
2019
Q1 		$125K Buy
+138
New +$125K ﹤0.01% 91

Other funds holding APTO

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nantahala Capital Management's APTO Position: Q4 2024 in Review

Nantahala Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q4 2024, closing a stake of 2,578 shares — an estimated $31.8K sold.

Nantahala Capital Management first reported a position in APTO in Q1 2019 and held it in 23 quarters. The position peaked at $46.2M in Q1 2021. 22 funds tracked by Wall St. Rank hold APTO as of Q4 2024.

  • Nantahala Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q4 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 2,578 Aptose Biosciences, Inc. shares in Q4 2024, an estimated $31.8K.
  • Nantahala Capital Management first reported a position in Aptose Biosciences, Inc. in Q1 2019 and held it in 23 quarters.
  • Nantahala Capital Management's Aptose Biosciences, Inc. position peaked at $46.2M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.